ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2275

Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies

Lucia Otero-Varela1, Carlos Sanchez-Piedra2, Elena Rabadán Rubio3, Juan Camilo Sarmiento-Monroy4, Chamaida Plasencia-Rodríguez5, Diana Sueiro6, Olga Martinez7, Noemí Busquets Pérez8, Mercedes Freire González9, Fernando Sánchez-Alonso10, José María Álvaro-Gracia11 and Isabel Castrejon12, and BIOBADASER group, 1Spanish Society of Rheumatology, Madrid, Spain, 2Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, 3Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, 4Hospital Clínic Barcelona, Barcelona, Spain, 5Hospital Universitario La Paz, MADRID, Spain, 6Complexo Hospitalario Universitario de Ourense, Ourense, Spain, 7Hospital Universitario de Salamanca, Zamora, Spain, 8HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, 9Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, 10Sociedad Española de Reumatología, Madrid, Spain, 11Hospital Gregorio Marañón, Madrid, Spain, 12Hospital General Universitario Gregorio Marañon, Madrid, Spain

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, longitudinal studies, registry, rheumatoid arthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: RA – Treatment Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients treated with tofacitinib, compared to patients treated with TNF inhibitors (TNFi). 

This study aimed to evaluate the safety of JAK inhibitors (JAKi) versus TNFi among patients with rheumatoid arthritis (RA) in a real-world setting.

Methods: Retrospective analysis of 3294 patients with RA included in a national registry of advanced therapies that collects adverse events data from routine clinical practice. A survival analysis was conducted comparing JAKi and TNFi initiated between 2017 and 2022, considering as a completion event the occurrence of specific adverse events (AEs): cardiac, vascular, MACE, and cancer (excluding non-melanoma skin cancer). Survival analysis was performed until the occurrence of the first AE, but excluding subsequent AEs. Hazard ratios (HR) were estimated using multivariate Cox regression model, adjusted by sex, age at treatment start, prior history of outcomes of interest, disease duration, and treatment line. Incidence rates were calculated as the number of events per 1.000 person-years, and Poisson regression was used to compute incidence rate ratios (IRR) comparing JAKi vs TNFi.

Results: A total of 1162 patients were treated with JAKi and 2624 with TNFi (Table 1). Both treatments were mostly used among females (81.9% vs 79.5%). JAKi were mainly used as third or later line of treatment (52.1%) while TNFi were used as first line of therapy (62.2%). JAKi presented HR greater than 1 for all AEs of interest: cardiac events HR 2.13 (95% confidence interval 1.43-3.18); vascular events HR 2.70 (95% CI 1.55–4.70); MACE HR 1.70 (95% IC 0.48-6.37); and malignancies HR 1.30 (95% CI 0.84-2.00). Table 2 depicts the IR calculated for each treatment group. No statistically significant differences were found among IRR, neither for the treatment groups nor the AE of interest.

Conclusion: Real-world data can be valuable and decisive when assessing the safety of JAKi. Two main findings should be highlighted from this study: on the one hand, the HR for cardiac and vascular events was statistically greater among JAKi compared to TNFi, and significant IRR was found for cardiac AEs. On the other hand, no differences were found in HR nor IRR for MACE and malignancies. Results from this analysis should be interpreted with caution due to the limited exposure time of JAKi and the differences in the patient profile using both treatment types (despite the adjusted regression models).

Supporting image 1

Supporting image 2

* IRR adjusted by sex, age at therapy start, disease duration, line of treatment, prior medical history of cardiovascular events, hypercholesterolemia, hypertension, obesity and smoking status
** IRR adjusted by sex, age at therapy start, disease duration, line of treatment, prior medical history of cancer, and smoking status.


Disclosures: L. Otero-Varela: None; C. Sanchez-Piedra: None; E. Rabadán Rubio: None; J. Sarmiento-Monroy: None; C. Plasencia-Rodríguez: None; D. Sueiro: None; O. Martinez: None; N. Busquets Pérez: None; M. Freire González: None; F. Sánchez-Alonso: None; J. Álvaro-Gracia: None; I. Castrejon: None.

To cite this abstract in AMA style:

Otero-Varela L, Sanchez-Piedra C, Rabadán Rubio E, Sarmiento-Monroy J, Plasencia-Rodríguez C, Sueiro D, Martinez O, Busquets Pérez N, Freire González M, Sánchez-Alonso F, Álvaro-Gracia J, Castrejon I. Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-and-cancer-safety-of-jaki-compared-to-tnfi-in-patients-with-rheumatoid-arthritis-results-from-a-national-registry-of-advanced-therapies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-and-cancer-safety-of-jaki-compared-to-tnfi-in-patients-with-rheumatoid-arthritis-results-from-a-national-registry-of-advanced-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology